Wegovy dose escalation and injection sites: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption, @kayleenicole._ is documenting her personal Wegovy journey, specifically noting she's on her last 0.25mg pen and planning to inject into her arm this week. This is classic GLP-1 community content: dose tracking, injection site experimentation, and week-by-week progress logging. She's likely sharing observations about tolerability at the starting dose, speculating about what comes next on the titration schedule, and possibly discussing site preference between abdomen, thigh, and upper arm. The PCOS hashtag suggests she may also be framing Wegovy as a treatment for PCOS-related weight gain, which is a claim worth examining carefully since semaglutide is not FDA-approved specifically for PCOS management. These personal journey videos are genuinely valuable for community support, but they often blur the line between anecdote and clinical fact.

What does the science actually show?

Wegovy (semaglutide 2.4mg weekly) was approved by the FDA in June 2021 based primarily on the STEP trial program. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo. The titration schedule starts at 0.25mg weekly for four weeks, then escalates in 0.25mg increments roughly every four weeks, reaching the 2.4mg maintenance dose. That 0.25mg starting dose is purely a tolerability measure, not a therapeutic dose. As for injection sites, a pharmacokinetic analysis published in Clinical Pharmacokinetics (Lau et al., 2021) found comparable absorption whether injected into the abdomen, thigh, or upper arm, so rotating sites is reasonable and clinically supported. The arm is a legitimate option, not a hack.

Where does the social media noise diverge from clinical reality?

A few patterns in GLP-1 TikTok content consistently drift from what studies actually show. First, the 0.25mg dose gets treated as meaningful for weight loss in these early-week videos, but it isn't. It's a ramp-up dose, and users sometimes mistake low early-week side effects at that dose for a sign they need to escalate faster or that the drug isn't working yet. Second, the PCOS framing is complicated. Small studies like Elkind-Hirsch et al. (2022, Journal of Clinical Endocrinology and Metabolism) suggest GLP-1 agonists may improve insulin resistance and androgen levels in PCOS, but these are preliminary findings in small cohorts, not evidence of an approved indication. Third, injection site lore on TikTok tends to overclaim differences between sites that pharmacokinetics studies simply don't support at the magnitude being described.

What should you actually know?

If you're starting Wegovy or watching someone else document their journey, a few things are worth keeping straight. The 0.25mg dose is not designed to produce weight loss. You are not behind if you don't see results in weeks one through four. The titration schedule exists because nausea, vomiting, and GI distress are significantly more common when patients jump to higher doses too quickly, as shown in the STEP trials where GI adverse events were the primary reason for discontinuation. Regarding injection sites, rotating between abdomen, thigh, and upper arm is recommended standard practice, and all three are clinically equivalent in absorption. For people with PCOS specifically, semaglutide may offer metabolic benefits, but anyone framing it as a PCOS treatment should be working with a clinician who understands the distinction between off-label use and an approved indication. Anecdotal results, even well-meaning ones, do not constitute medical guidance.